-The Hindu Union Commerce and Industry Minister Anand Sharma has termed "historic" the Supreme Court's rejection of Novartis' claim for patent for its anti-cancer drug Glivec. He said the Indian Patent Act was in conformity with its international obligations under the Trade Related Aspects of Intellectual Property Rights Agreement. "It is a historic judgment. It reaffirms the position of Indian law and, in particular, provisions of Section 3D, which mandates... a substantive...

-The Hindu   The government does it purely on the strength of a certificate issued by the district administration Even as the recent affidavit submitted by the Union Ministry of Environment and Forests (MoEF) before the Supreme Court in the Vedanta case has caused dismay among tribal communities and activists for the dilution of its stand on diverting forest lands of tribal communities, the Ministry has gone a step further and allowed diversion...

-Tehelka A public issue is not truly public unless Markandey Katju has passed judgement. Rahul Kotiyal and Ajachi Chakrabarti stand downwind "Journalists" writes Markandey Katju, with little sense of irony, "comment on everything under the sun." He goes on to say that when the shoe is on the other foot, when someone comments on journalism, it is misconstrued as an attack on press freedom. That when he announces he is appointing a...

-The Telegraph The Supreme Court has held that criminal cases, particularly corruption-related, cannot be quashed because of prolonged delay in trial. The recent ruling assumes significance against the backdrop of a pile-up in cases and a perception fuelled by time lag that those charged with corruption usually get away lightly. The Supreme Court's decision came while it refused to quash a 27-year-old graft case filed by the anti-corruption bureau against the then deputy...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...